Replies to post #644 on Enanta Pharmaceuticals Inc (ENTA)

[stockbettor]

HCV treatment breakthroughs highlighted at ACG 2014

I found the pre-recorded comments on both oral papers to be of interest, particularly #5 highlighting the potential for liver improvement in cirrhotic patients following treatment.

http://www.sciencecodex.com/hcv_treatment_breakthroughs_highlighted_at_acg_2014-143793

Virtual Press Briefings Include Expert Commentary, Author Insight on the Following Abstracts:

Hepatitis C (HCV) Listen to the briefing

Oral Paper 4 SVR12 (sustained virologic response 12 weeks post-treatment) of 99% Achieved with a Ribavirin-Free Regiment of ABT-450r Ombitasvir and Dasabuvir in HCV Genotype 1b-Infected Patients Read author insight and access abstract

Oral Paper 5 Normalization of Liver-Related Laboratory Parameters in HCV Genotype 1-Infected Patients with Cirrhosis after Treatment With ABT -450/R/Ombitasvir, Dasabuvir and Ribavirin Read author insight and access abstract